Back to Journals » Clinical, Cosmetic and Investigational Dermatology » Volume 3

Botulinum toxin type A for the management of glabellar rhytids

Authors Tremaine AM

Published 7 April 2010 Volume 2010:3 Pages 15—23


Review by Single anonymous peer review

Peer reviewer comments 4

Anne Marie Tremaine, Jerry L McCullough

Department of Dermatology, University of California, Irvine, CA, USA

Abstract: There is an increasing demand for minimally-invasive cosmetic procedures to arrest the aging process. Botulinum toxin type A injections are the most commonly used nonsurgical cosmetic procedures in the United States. There has been research spanning over two decades dedicated to safety, efficacy, dosing, and complications of botulinum toxin type A. There are now two Food and Drug Administration (FDA) approved botulinum toxin type A options in the United States: Botox® and Dysport™, with new advances being made in the field.

Keywords: botulinum toxin type A, glabella, Botox, Dysport, complications, dosing

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.